|Assessment Status||Rapid Review Complete|
|Indication||For the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.|
|Rapid review commissioned||15/11/2021|
|Rapid review completed||30/11/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that tirbanibulin not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.